GHRP-2: Regulatory Status
Current legal and regulatory status for GHRP-2 across jurisdictions. This page reflects the most recent verified information and is updated as regulatory actions occur.
Back to GHRP-2 overviewUnited States
Compoundable (503A)
Prescription required
Compounding status: available through compounding pharmacies and research suppliers. WADA: prohibited (S2 — peptide hormones, growth factors). approved in Japan as diagnostic agent for GH deficiency (pralmorelin / GHRP Kaken 100); not approved therapeutically anywhere
What This Means
Compoundable does not mean FDA approved.
GHRP-2 is available through licensed 503A compounding pharmacies with a physician's prescription. This is a regulatory pathway, not an endorsement of efficacy for any specific indication. All use is off-label.
Reclassification is not the same as FDA approval.
Even if GHRP-2 moves to Category 1, it remains an off-label therapeutic that requires physician supervision. Category 1 means it can be compounded under section 503A — it does not confer approved-drug status.